Empagliflozin study for adults with major depression
About this title
Read the official source — NCT05757791Researchers studied Empagliflozin to find out how it affected depression symptoms in people with depression.
Understand this study
What did researchers investigate?
Researchers studied Empagliflozin to find out how it affected depression symptoms in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- NYU Langone Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05757791
- Official title
Show the full official title
A Pilot, Phase II, Open-Label, Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
New York
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Empagliflozin to find out how it affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is NYU Langone Health.
Did this study involve medication?
Yes. The study involved medication, including Empagliflozin.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
